| Molecular formula | C194H312N54O59S2 |
|---|
| Molecular weight | 4409 g/mol |
|---|
| Registered trials | 45 |
|---|
| PubChem CID | 171397054 |
|---|
Regulatory status
Cagrilintide is an investigational compound. It does not have an approved drug label, and no regulatory agency has cleared it for medical use. Any research findings described below relate to ongoing clinical study, not an established use.
What cagrilintide is
Cagrilintide is a long chain peptide with the molecular formula C194H312N54O59S2 and a molecular weight of approximately 4,409 g/mol (PubChem CID 171397054). Because it lacks an approved label, there is no FDA-defined mechanism, indication, or dosing information to report.
Trial footprint
Cagrilintide has 45 registered clinical trials. Sampled studies include a trial comparing two injectable versions of cagrilintide against placebo in people with excess body weight, a study examining how a cagrilintide and semaglutide combination affects food intake, appetite, and stomach emptying, and a study comparing blood levels of cagrilintide and semaglutide given together versus separately. These trials involve people with overweight or obesity and remain part of an active research program.
FAQ
No. Cagrilintide is an investigational compound and does not currently have an FDA-approved label or indication. It remains under study in clinical trials.
Cagrilintide is a peptide with the molecular formula C194H312N54O59S2 and a molecular weight of about 4,409 g/mol. It is cataloged in PubChem under CID 171397054.
There are 45 registered clinical trials involving cagrilintide. Sampled trials include studies in people with excess body weight or obesity, some evaluating it alongside semaglutide.
CagriSema is a name used in trials that study cagrilintide combined with semaglutide. Registered studies have looked at its effects on food intake, appetite, and stomach emptying, as well as combined versus separate injection blood levels.
No adverse event report data was available for cagrilintide at this time. Because it is investigational, safety information is limited to what is disclosed within individual clinical trial results.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19